Home › Therapeutic areas › Renal › Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis (4 companies)
Companies with an active program in Focal Segmental Glomerulosclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $5.4M | 7 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 2 | Approved | $4.76B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $2.15B | 6 |
No companies match.